Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 9 at 1:30 PM PT. The presentation will be accessible via a live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on utilizing the adaptive immune system for diagnosing and treating diseases, with products and pipelines aimed at cancer, autoimmune disorders, and infectious diseases. Their proprietary platform enhances drug development and clinical diagnostics.

SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Adaptive Biotechnologies’ management is scheduled to present on Monday, January 9^th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Mary Pat Lancelotta
206-600-6702
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies present at the J.P. Morgan Healthcare Conference?

Adaptive Biotechnologies will present on January 9, 2023, at 1:30 PM Pacific Time.

How can I access the presentation by Adaptive Biotechnologies?

You can access the live and archived webcast of the presentation on the 'Investors' section of the Adaptive Biotechnologies website.

What is the main focus of Adaptive Biotechnologies as stated in the press release?

Adaptive Biotechnologies focuses on harnessing the adaptive immune system to develop clinical products for diagnosing and treating diseases, including cancer and autoimmune disorders.

What date is the 41st Annual J.P. Morgan Healthcare Conference?

The 41st Annual J.P. Morgan Healthcare Conference is scheduled for January 9, 2023.

What stock symbol is associated with Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.